Accustem Sciences Inc. (ACUT) stock
Close on Oct 16, 2026Market cap $2.37MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $2.37M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$1.65M
- EPS, diluted
- -$0.10
- Book value per share
- -$0.26
- Diluted shares
- 16M
Trading
- Previous close
- $0.15
- Open
- $0.15
- Day's range
- $0.15 – $0.15
- Volume
- 0
- Average volume (20 days)
- 2,549
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 16, 2026. The S&P 500 is measured by the SPY fund.
| Period | ACUT | S&P 500 | Difference | ACUT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +13.2% | +1.5% | +11.8 pts | ||
| 3 months | -28.1% | +1.9% | −30.0 pts | ||
| Year to date | -81.9% | +12.8% | −94.7 pts | ||
| 1 year | -85.5% | +16.8% | −102.3 pts | ||
| 3 years | -79.0% | +81.5% | −160.5 pts | -40.6% | +22.0% |
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Accustem Sciences filed with the SEC as exhibits to Form 8-K or 6-K
- Update
About Accustem Sciences
Pharmaceutical Preparations
AccuStem Sciences, Inc. is a clinical-stage diagnostics company that develops and commercializes genomic tests to assist decision-making across oncology care. Its proprietary test pipeline includes the MicroRNA Signature Classifier, a 24-microRNA blood-based assay designed to determine whether lung nodules identified through low-dose computed tomography screening are benign or malignant. The company also develops StemPrintER, a 20-gene prognostic assay measuring tumor stemness to evaluate the risk of distant recurrence in patients diagnosed with early-stage, luminal breast cancer. Additionally, it plans to provide ancillary testing services such as hereditary genetic and somatic mutation panels.
Company profile, executives and historyAccustem Sciences stock: common questions
What is Accustem Sciences's stock price?
ACUT closed at $0.15 on Oct 16, 2026, up 0.00% on the day.
What is Accustem Sciences's market cap?
Accustem Sciences was worth $2.37M at the close on Oct 16, 2026: the share price times the diluted shares outstanding.
What is ACUT's P/E ratio?
Accustem Sciences lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.10), so it has no meaningful P/E ratio.
Does Accustem Sciences pay a dividend?
No. Accustem Sciences has not paid a cash dividend over the last twelve months.
How has ACUT stock performed over the past year?
Including dividends, ACUT returned -85.5% over the past year, against +16.8% for the S&P 500.
Who are Accustem Sciences's competitors?
Companies most similar to Accustem Sciences by business, industry and size include ALLR, ONCO, ACRV, ATNM, GNPX.
See a number that looks wrong?